РАПТОВА СЕРЦЕВА СМЕРТЬ: ФАКТОРИ РИЗИКУ, ПРИЧИНИ, ПРЕДИКТОРИ (ОГЛЯД ЛІТЕРАТУРИ)
PDF

Ключові слова

раптова серцева смерть
маркери
причини
фактори ризику

Як цитувати

Уварова, К. (2019). РАПТОВА СЕРЦЕВА СМЕРТЬ: ФАКТОРИ РИЗИКУ, ПРИЧИНИ, ПРЕДИКТОРИ (ОГЛЯД ЛІТЕРАТУРИ). Молодий вчений, 11 (75), 726-732. https://doi.org/10.32839/2304-5809/2019-11-75-154

Анотація

Під раптовою серцевою смертю (РСС) розуміють несподівану зупинку серцевої діяльності або смерть у результаті наявних серцево-судинних захворювань. У 2012 році в Україні було зареєстровано понад 72 тис смертей від серцево-судинних захворювань. У даній статті розглядаються особливості епідеміології РСС в Україні та за кордоном, а також фактори ризику її розвитку. Приділяється належна увага основним причинам виникнення та електрокардіографічним предикторам РСС. Обговорюються питання щодо нових молекулярних біомаркерів і тих, що вже давно зарекомендували себе в якості предикторів даної нозології: маркерів серцево-судинних захворювань, запалення, гемодинамічних, міокардіальних стресових і нейрогормональних біомаркерів. Визначення розглянутих молекулярних предикторів може використовуватися для профілактики та прогнозу РСС. В огляді використовувалися закордонні літературні джерела останніх років.

https://doi.org/10.32839/2304-5809/2019-11-75-154
PDF

Посилання

Myerburg R., Juhani J. Sudden cardiac death caused by coronary heart disease. Circulation. 2012. Vol. 125. №8. Pp. 1043–1052.

Goldberger J., Buxton A., Cain M. et al. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation. 2011. Vol. 123. № 21. Pp. 2423–2430.

Albert C., Chae C., Grodsteinet F. et al. Prospective study of sudden cardiac death among women in the United States. Circulation. 2003. Vol. 107. №16. Pp. 2096–2101.

Chugh S. Sudden cardiac death in 2017: spotlight on prediction and prevention. International journal of cardiology. 2017. Vol. 237. Pp. 2–5.

Fishman G., Chugh S., DiMarco J. et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation. 2010. Vol. 122. №22. Pp. 2335–2348.

Mozaffarian D., Benjamin E., Go A. et al. Heart disease and stroke statistics-2016 update a report from the American Heart Association. Circulation. 2016. Vol. 133. №14. Pp. 38–48.

Benjamin E., Blaha M., Chiuve S. et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017. Vol. 135. №10. Pp. 146–603.

Merchant R., Yang L., Becker L. et al. Incidence of treated cardiac arrest in hospitalized patients in the United States. Critical care medicine. 2011. Vol. 39. №11. Pp. 2401.

Zhang S. Sudden cardiac death in China: current status and future perspectives. EP Europace. 2016. Vol. 17. Pp. ii14–ii18.

Weisfeldt M., Everson-Stewart S., Sitlani C. etal. Ventricular tachyarrhythmias after cardiac arrest in public versus at home. New England Journal of Medicine. 2011. Vol. 364. №4. Pp. 313–321.

Chugh S., Jui J., Gunson K. et al. Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large US community. Journal of the American College of Cardiology. 2004. Vol. 44. №6. Pp. 1268–1275.

Winkel B., Jabbari R., Tfelt-Hansen J. How to prevent SCD in the young? International journal of cardiology. 2017. Vol. 237. Pp. 6–9.

Faragli A., Underwood K., Priori S. et al. Is there a role for genetics in the prevention of sudden cardiac death? Journal of cardiovascular electrophysiology. 2016. Vol. 27. №9. Pp. 1124–1132.

Haukilahti M., Holmström, L., Vähätalo, J. et al. Sudden Cardiac Death in Women: Causes of Death, Autopsy Findings, and Electrocardiographic Risk Markers. Circulation. 2019. Vol. 139. №8. Pp. 1012–1021.

Shah K., Shah A., Bhopal R. Systematic review and meta-analysis of out-of-hospital cardiac arrest and race or ethnicity: black US populations fare worse. European journal of preventive cardiology. 2014. Vol. 21. №5. Pp. 619–638.

Wong C., Brown A., Lau D. et al. Epidemiology of sudden cardiac death: global and regional perspectives. Heart, Lung and Circulation. 2019. Vol. 28. №1. Pp. 6–14.

Hayashi M., Wataru S., Albert C. The spectrum of epidemiology underlying sudden cardiac death. Circulation research. 2015. Vol. 116. №12. Pp. 1887–1906.

Aro A., Reinier K., Rusinaru C. et al. Electrical risk score beyond the left ventricular ejection fraction: prediction of sudden cardiac death in the Oregon Sudden Unexpected Death Study and the Atherosclerosis Risk in Communities Study. European heart journal. 2017. Vol. 38. №40. Pp. 3017–3025.

Chen L., Sotoodehnia N., Bůžková P. et al. Atrial fibrillation and the risk of sudden cardiac death: the atherosclerosis risk in communities study and cardiovascular health study. JAMA internal medicine. 2013. Vol. 173. №1. Pp. 29–35.

Deo R., Norby F., Katz R. et al. Development and validation of a sudden cardiac death prediction model for the general population. Circulation. 2016. Vol. 134. №11. Pp. 806–816.

Gami A., Olson E., Shen W.et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. Journal of the American College of Cardiology. 2013. Vol. 62. №7. Pp. 610–616.

Hayashi M., Shimizu W., Albert C. The spectrum of epidemiology underlying sudden cardiac death. Circ Res. 2015. Vol. 116. Pp. 1887–906.

Rosenthal T., Masvidal D., Abi Samra F. et al. Optimal method of measuring the T-peak to T-end interval for risk stratification in primary prevention. Ep Europace. 2017. Vol. 20. №4. Pp. 698–705.

Dinshaw L., Münch J., Dickow J. et al. The T-peak-to-T-end interval: a novel ECG marker for ventricular arrhythmia and appropriate ICD therapy in patients with hypertrophic cardiomyopathy. Clinical Research in Cardiology. 2018. Vol. 107. №2. Pp. 130–137.

Rosenthal T., Stahls P., Samra F. et al. T-peak to T-end interval for prediction of ventricular tachyarrhythmia and mortality in a primary prevention population with systolic cardiomyopathy. Heart Rhythm. 2015. Vol. 12. №8. Pp. 1789–1797.

Genovesi S., Boriani G., Covic A. et al. Sudden cardiac death in dialysis patients: different causes and management strategies. Nephrology Dialysis Transplantation. 2019 Vol. 34. P. 1–10.

Empana J., Boulanger C., Tafflet M.et al. Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) study. European Heart Journal: Acute Cardiovascular Care. 2015. Vol. 4. №1. Pp. 28–36.

Leibowitz M., Cohen-Stavi C., Basu S.et al. Targeting LDL cholesterol: beyond absolute goals toward personalized risk. Current cardiology reports. 2017. Vol. 19. №6. P. 52.

Arca M., Borghi C., Pontremoli R. et al. Hypertriglyceridemia and omega-3 fatty acids: Their often overlooked role in cardiovascular disease prevention. Nutrition, Metabolism and Cardiovascular Diseases. 2018. Vol. 28. №3. Pp. 197–205.

Reinier K., Narayanan K., Uy-Evanado A. et al. Electrocardiographic markers and left ventricular ejection fraction have cumulative effects on Risk of Sudden Cardiac Death. JACC: Clinical Electrophysiology. 2015. Vol. 1. №6. Pp. 542–550.

Tseng Z., Olgin J., Vittinghoff E. et al. Prospective countywide surveillance and autopsy characterization of sudden cardiac death: POST SCD Study. Circulation. 2018. Vol. 137. №25. Pp. 2689–2700.

Narayan S., Paul J., James P. New concepts in sudden cardiac arrest to address an intractable epidemic: JACC state-of-the-art review. Journal of the American College of Cardiology. 2019. Vol. 73. №1. Pp. 70–88.

Katritsis D., Bernard J., John C. A clinical perspective on sudden cardiac death. Arrhythmia & electrophysiology review. 2016. Vol. 5. №3. P. 177.

Yow A., Sandeep S. Sudden Cardiac Death. StatPearls [Internet]. StatPearls Publishing, 2019.

de Luna A., van-Roessel A., Escobar-Robledo L. et al. Update on sudden cardiac death: Epidemiology and risk stratification. Spanish Journal of Legal Medicine. 2018. Vol. 44. №1. Pp. 5–12.

Osman J., Tan S., Lee P. et al. Sudden Cardiac Death (SCD) – risk stratification and prediction with molecular biomarkers. Journal of biomedical science. 2019. Vol. 26. №1. Pp. 39.

Wang J., Tan G. J., Han L. et al. Novel biomarkers for cardiovascular risk prediction. J Geriatr Cardiol. 2017. Vol. 14. Pp. 135–150.

Dhindsa D., Khambhati J., Sandesara P.et al. Biomarkers to predict cardiovascular death. Cardiac electrophysiology clinics 2017. Vol. 9. №4. Pp. 651–664.

Patel R., Ghasemzadeh N., Eapen D. et al. Novel biomarker of oxidative stress is associated with risk of death in patients with coronary artery disease. Circulation. 2016. Vol. 133. Pp. 361–369.

Bernadett K., Greensmith L. Induction of heat shock proteins for protection against oxidative stress. Advanced drug delivery reviews. 2009. Vol. 61. №4. Pp. 310–318.

Zhu J., Quyyumi A., Wu H. et al. Increased serum levels of heat shock protein 70 are associated with low risk of coronary artery disease. Arteriosclerosis, thrombosis, and vascular biology. 2003. Vol. 23. №6. Pp. 1055–1059.

Lei Z., Wang X., and Yang Y. Association between interleukin-6 and the risk of cardiac events measured by coronary computed tomography angiography. The international journal of cardiovascular imaging. 2017. Vol. 33. №8. Pp. 1237–1244.

Cainzos-Achirica M., Enjuanes C., Greenland P. et al. The prognostic value of interleukin 6 in multiple chronic diseases and all-cause death: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2018. Vol. 278. Pp. 217–225.

Sobel B., Hardison R., Genuth S. et al. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation. 2011. Vol. 124. №6. Pp. 695–703.

Korngold E., Januzzi J., Gantzer ML et al. Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation. 2009. Vol. 119. Pp. 2868–2876.

Empana J., Jouven X., Canouï-Poitrine F. et al. C-reactive protein, interleukin 6, fibrinogen and risk of sudden death in European middle-aged men: the PRIME study. Arteriosclerosis, thrombosis, and vascular biology. 2010. Vol. 30. №10. Pp. 2047–2052.

Mahajan K. Interleukin-18 and atherosclerosis: mediator or biomarker. J Clin Exp Cardiolog 2014. Vol. 5. Pp. 1–4.

Opstad T., Arnesen H., Pettersen A. et al. Combined elevated levels of the proinflammatory cytokines IL-18 and IL-12 are associated with clinical events in patients with coronary artery disease: an observational study. Metabolic syndrome and related disorders. 2016. Vol. 14. №5. Pp. 242–248.

Parrinello C., Lutsey P., Ballantyne C. et al. Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. American heart journal. 2015. Vol. 170. №2. Pp. 380–389.

Holst-Albrechtsen S., Kjaergaard M., Thi Huynh A. et al. Can lipoprotein-associated phospholipase A2 be used as a predictor of long-term outcome in patients with acute coronary syndrome? Current cardiology reviews. 2013. Vol. 9. №4. Pp. 310–315.

Yang L., Cong H., Wang S. et al. AMP-activated protein kinase mediates the effects of lipoprotein-associated phospholipase A2 on endothelial dysfunction in atherosclerosis. Experimental and therapeutic medicine. 2017. Vol. 13. №4. Pp. 1622–1629.

Yang L., Wang H., Zhang Y. et al. The prognostic value of lipoprotein-associated phospholipase A2 in the long-term care of patients with acute coronary syndrome undergoing percutaneous coronary intervention. Clinical and Applied Thrombosis/Hemostasis. 2018. Vol. 24. №5. Pp. 822–827.

Teng N., Maghzal G., Talib J. et al. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Report. 2017. Vol. 22. №2. Pp. 51–73.

Hansson G., Peter L., Ira T. Inflammation and plaque vulnerability. Journal of internal medicine. 2015. Vol. 278. №5. Pp. 483–493.

Ghasemzadeh N., Hayek S., Ko Y. et al. Pathway-specific aggregate biomarker risk score is associated with burden of coronary artery disease and predicts near-term risk of myocardial infarction and death. Circulation: Cardiovascular Quality and Outcomes. 2017. Vol. 10. №3. P. 001493.

Eapen D., Manocha P., Ghasemzadeh N et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. Journal of the American heart association. 2014. Vol. 3. №5. P. 001118.

Tazaki R., Tanigawa J., Fujisaka T.et al. Plasma pentraxin3 level is associated with plaque vulnerability assessed by optical coherence tomography in patients with coronary artery disease. International heart journal. 2016. Vol. 57. №1. Pp. 18–24.

Swords J., Blumenthal R., Kronmal R. et al. Associations of pentraxin 3 with cardiovascular disease: the M ulti‐E thnic S tudy of A therosclerosis. Journal of Thrombosis and Haemostasis. 2014. Vol. 12. №6. Pp. 999–1005.

Chu J, Jones G., Tarr G. et al. Plasma active matrix metalloproteinase 9 and indices of diastolic function in patients with preserved systolic function. International journal of cardiology. 2013. Vol. 167. №4. Pp. 1242–1246.

Peeters S., Engelen L., Buijs J. et al. Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovascular diabetology. 2017. Vol. 16. №1. P. 55.

Peacock W. Novel biomarkers in acute heart failure: MR-pro-adrenomedullin. Clinical Chemistry and Laboratory Medicine (CCLM). 2014. Vol. 52. №10. Pp. 1433–1435.

Louise B., Gustafsson F. Copeptin as a biomarker in heart failure. Biomarkers in medicine. 2014. Vol. 8. №6. Pp. 841–854.

Everett B., Brooks M., Vlachos H. et al. Troponin and cardiac events in stable ischemic heart disease and diabetes. New England Journal of Medicine. 2015. Vol. 373. №7. Pp. 610–620.

Nakamura H., Niwano S., Fukaya H et al. Cardiac troponin T as a predictor of cardiac death in patients with left ventricular dysfunction. Journal of arrhythmia. 2017. Vol. 33. №5. Pp. 463–468.

Thygesen K., Alpert J., Jaffe A. et al. Fourth universal definition of myocardial infarction (2018). Journal of the American College of Cardiology. 2018. Vol. 72. №18. Pp. 2231–2264.

Sze J., Mooney J., Barzi F.et al. Cardiac troponin and its relationship to cardiovascular outcomes in community populations–a systematic review and meta-analysis. Heart, Lung and Circulation. 2016. Vol. 25. №3. Pp. 217–228.

Kai E., Jernberg T., Lindahl B. Cardiac troponin elevation in patients without a specific diagnosis. Journal of the American College of Cardiology. 2019. Vol. 73. №1. Pp. 1–9.

Roos A., Bandstein N., Lundbäck M. et al. Stable high-sensitivity cardiac troponin T levels and outcomes in patients with chest pain. Journal of the American college of cardiology. 2017. Vol. 70. №18. Pp. 2226–2236.

Icer M., Gezmen-Karadag M. The multiple functions and mechanisms of osteopontin. Clinical biochemistry. 2018. Vol. 59. Pp. 17–24.

Sakamuri S., Takawale A., Basu R. et al. Differential impact of mechanical unloading on structural and nonstructural components of the extracellular matrix in advanced human heart failure. Translational Research. 2016. Vol.172. Pp. 30–44.

Dalal S., Zha Q., Daniels C. R. et al. Osteopontin stimulates apoptosis in adult cardiac myocytes via the involvement of CD44 receptors, mitochondrial death pathway, and endoplasmic reticulum stress. American Journal of Physiology-Heart and Circulatory Physiology. 2014. Vol. 306. №8. Pp. 1182–1191.

Maalouf R., Bailey S. A review on B-type natriuretic peptide monitoring: assays and biosensors. Heart failure reviews. 2016.Vol. 21. №5. Pp. 567–578.

Chow S., Maisel A., Anand I. et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017. Vol. 135. №22. Pp. 1054–1091.

Cocco G., Jerie P. Assessing the benefits of natriuretic peptides-guided therapy in chronic heart failure. Cardiology journal. 2015. Vol. 22. №1. Pp. 5–11.

Rubattu S., Forte M., Marchitti S. et al. Molecular implications of natriuretic peptides in the protection from hypertension and target organ damage development. International journal of molecular sciences. 2019. Vol. 20. №4. P. 798.

Al-Khatib S., Stevenson W., Ackerman M. et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology. 2018. Vol. 72. №14. Pp. 91–220.

Nesarhoseini V., Rasooli M., Taghipour Me. Serum aldosterone and coronary artery disease. Vascul Dis Ther. 2016. Vol. 1. №1. Pp. 1–3.

Maisel A., Mueller C., Neath S. et al. Copeptin helps in the early detection of patients with acute myocardial infarction: primary results of the CHOPIN trial (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction). Journal of the american college of cardiology. 2013. Vol. 62. №2. Pp. 150–160.

Pek J., Fook-Chong S., Choo J. et al. Copeptin, myeloperoxidase and pro-adrenomedullin for acute coronary syndrome in patients with chronic kidney disease. Proceedings of Singapore Healthcare. 2019. Vol. 28. № 3. Pp. 173–183.

Willeit P., Kaptoge S., Welsh P.et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. The Lancet Diabetes & Endocrinology. 2016. Vol. 4. №10. Pp. 840–849.

Hartupee J., Douglas L. Neurohormonal activation in heart failure with reduced ejection fraction. Nature Reviews Cardiology. 2017. Vol. 14. №1. Pp. 30–38.

Zhang X., Sessa W., Fernández-Hernando C. Endothelial transcytosis of lipoproteins in atherosclerosis. Frontiers in cardiovascular medicine. 2018. Vol. 5. P. 130.